Hyperbaric oxygen therapy addresses the tissue ischemia driving scleroderma’s most difficult complications
Understanding scleroderma’s vascular complications and how HBOT addresses the tissue ischemia driving them
Scleroderma — formally called systemic sclerosis (SSc) — is a chronic autoimmune connective tissue disease characterized by progressive fibrosis of the skin and internal organs, and by widespread damage to the small blood vessels (microvasculopathy) that supply them. It affects approximately 300,000 Americans and is significantly more common in women than men. Scleroderma presents in two main forms: limited cutaneous systemic sclerosis (formerly CREST syndrome), in which skin involvement is restricted to the hands, face and forearms; and diffuse cutaneous systemic sclerosis, in which fibrosis involves larger areas of the trunk, arms and legs and progresses more rapidly to internal organ involvement.
The microvascular destruction of scleroderma is its most clinically immediate source of suffering. Endothelial dysfunction and progressive obliteration of digital and cutaneous capillaries create tissue that is chronically oxygen-deprived — unable to sustain normal cellular metabolism, heal injuries or resist infection. The two most common vascular complications are Raynaud’s phenomenon — episodic, often severely painful vasospasm of the fingers triggered by cold or stress, causing color changes and ischemic pain — and digital ulcers, which develop in up to 50% of scleroderma patients and represent areas of ischemic skin breakdown on the fingertips and over bony prominences of the hands.
Digital ulcers in scleroderma are notoriously difficult to heal. The same microvascular destruction that caused the ulcer also prevents normal healing — the wound bed is ischemic, hypoxic and unable to support the fibroblast activity, angiogenesis and immune function required for closure. Without adequate wound healing capacity, digital ulcers can persist for months, become infected, and in severe cases progress to digital gangrene requiring amputation.
HBOT directly addresses the central problem: tissue hypoxia in scleroderma-damaged skin and fingers. By dissolving oxygen into plasma at concentrations far exceeding what compromised scleroderma microvasculature can deliver, HBOT restores the oxygen supply to ischemic tissue via diffusion — bypassing the damaged capillaries entirely. Simultaneously, HBOT stimulates angiogenesis (new capillary formation) through VEGF upregulation, progressively improving baseline perfusion. Published clinical evidence, while modest in volume given the rarity of the disease, supports meaningful improvements in digital ulcer healing, Raynaud’s severity and pain in scleroderma patients treated with HBOT.
Raynaud’s phenomenon — episodes of finger color change (white, blue, red), ischemic pain and numbness triggered by cold or stress
Digital ulcers — painful, slow-healing wounds on fingertips and finger joints
Progressive skin thickening, tightening and hardening (sclerodactyly in the fingers)
Telangiectasias (small dilated blood vessels visible on skin surface)
Joint pain, stiffness and reduced hand mobility from skin and subcutaneous fibrosis
Internal organ involvement — pulmonary fibrosis, pulmonary hypertension, renal crisis, GI dysmotility — in diffuse systemic sclerosis
How HBOT addresses scleroderma’s vascular and wound complications
Scleroderma’s most painful complications — digital ulcers, Raynaud’s phenomenon and non-healing wounds — all share the common mechanism of tissue ischemia and hypoxia that HBOT directly addresses.
Heals digital ulcers and prevents tissue loss in the fingers
Reduces the severity and frequency of Raynaud’s attacks
Stimulates new capillary growth in ischemic tissue
Reduces pain and improves hand function
Reduces skin fibrosis and softens sclerotic skin
Supports healing of non-digital scleroderma skin wounds
For Providers
Clinical evidence for HBOT in scleroderma
The evidence base for HBOT in scleroderma is limited by the rarity of the condition, but the published data support meaningful benefit in digital ulcers and Raynaud’s phenomenon, and the mechanistic rationale is strong.
Yildiz et al. — controlled study in scleroderma (2004): The most significant published study of HBOT specifically in scleroderma, Yildiz and colleagues enrolled scleroderma patients with Raynaud’s phenomenon and digital ulcers and compared HBOT to standard medical management alone. The HBOT group demonstrated statistically significant improvements in Raynaud’s condition score, digital ulcer healing rates and pain visual analogue scale scores compared to the control group. The study also reported improvement in capillaroscopy findings — an objective measure of microvascular architecture — suggesting that HBOT’s angiogenic effects produce real structural improvement in scleroderma’s damaged microvasculature, not merely symptomatic relief. [Yildiz S et al. Joint Bone Spine. 2004;71(6):532–536. PMID: 15589437]
Capillaroscopy evidence — angiogenesis confirmed: Nailfold capillaroscopy — the gold standard imaging technique for scleroderma microvasculature — has documented measurable improvements in capillary density and architecture following HBOT in scleroderma patients. New capillary formation in the nailfold correlates with the clinical improvements in Raynaud’s severity and digital perfusion, providing objective imaging evidence that HBOT’s angiogenic mechanism is active in scleroderma tissue.
Digital ulcer mechanism: Scleroderma digital ulcers fail to heal through the same fundamental mechanism as other hypoxic wounds: tissue oxygen tension is below the threshold required for fibroblast proliferation, collagen synthesis, angiogenesis and neutrophil oxidative killing. HBOT raises wound tissue oxygen to levels that restore all of these healing processes. The HBOT mechanism that drives 76% resolution rates in radiation-induced hemorrhagic cystitis and accelerates diabetic foot wound closure is the same mechanism operating in scleroderma digital ulcers. The evidence base is smaller due to patient numbers, not due to any difference in mechanism.
Raynaud’s phenomenon — the HBOT angiogenesis rationale: Raynaud’s severity in scleroderma correlates directly with capillary loss in the nailfold. Each episode of vasospasm further ischemia-injures already compromised capillaries. HBOT’s documented capacity to stimulate new collateral capillary formation provides a disease-modifying mechanism for Raynaud’s in scleroderma — not merely a symptomatic vasodilator effect, but actual neovascularization that increases the capillary reserve available to perfuse the fingers during vasospasm episodes. [Thom SR et al. Am J Physiol Heart Circ Physiol. 2011;300(1):H294–305. PMID: 21057048]
Parallel wound evidence: While the scleroderma-specific evidence base is modest in size, HBOT’s effectiveness in other forms of ischemic wound — diabetic foot ulcers, arterial insufficiency ulcers, radiation wounds — rests on identical mechanisms to those operating in scleroderma digital ulcers. The tissue hypoxia, angiogenic deficiency and immune dysfunction driving failed healing are common to all these wound types, and HBOT addresses them through the same well-documented pathways.
Honest assessment of evidence quality: We are transparent that the scleroderma HBOT evidence base consists primarily of one controlled study and several case series, rather than large randomized controlled trials. The rarity of scleroderma makes definitive RCTs logistically challenging, but the existing evidence is internally consistent, mechanistically well-supported and supported by objective outcome measures. We discuss realistic expectations based on your specific disease severity and digital ulcer status at your consultation.
Our scleroderma HBOT protocol at Bay Area Hyperbarics
HBOT for scleroderma targets the ischemic tissue consequences of the disease’s vasculopathy — particularly digital ulcers and Raynaud’s phenomenon — rather than the underlying autoimmune and fibrotic disease process itself. It works best as an adjunct to rheumatological care and is most effective for patients with active digital ulcers or severe Raynaud’s where tissue ischemia is the primary clinical problem.
Rheumatology assessment and coordinated care planning
Our medical team reviews your scleroderma subtype (limited or diffuse), disease duration, skin score, digital ulcer history, Raynaud’s severity, current medications and treatment goals. We coordinate with your rheumatologist to integrate HBOT as an adjunct to your systemic scleroderma management — not as a replacement for disease-modifying therapy.
HBOT sessions to restore tissue oxygenation and support healing
You breathe 100% oxygen at 2.0 to 2.4 atmospheres absolute for approximately 90 minutes per session, once daily. Scleroderma protocols typically involve 20 to 40 sessions as an initial course, with digital ulcer healing and Raynaud’s symptom reassessment at completion. Sessions are scheduled around your other medical appointments and infusion schedules.
Monitoring and maintenance planning
We track digital ulcer healing, Raynaud’s attack frequency and severity, pain scores and hand function throughout treatment. Given the progressive and chronic nature of scleroderma, periodic maintenance HBOT courses — particularly during winter months when Raynaud’s is most severe — can help sustain vascular improvements achieved.
Frequently Asked Questions
Answers to the questions scleroderma patients most often ask about hyperbaric oxygen therapy.
HBOT addresses the ischemic tissue consequences of scleroderma’s vasculopathy — primarily digital ulcers, Raynaud’s phenomenon and non-healing skin wounds — rather than the underlying autoimmune disease process or the systemic fibrosis. Disease-modifying treatment of scleroderma itself requires immunosuppressive and antifibrotic medications managed by a rheumatologist. HBOT is a meaningful adjunct for the vascular and wound complications, working alongside systemic therapy rather than replacing it.
The evidence base for HBOT in scleroderma is limited by the rarity of the disease, but includes controlled studies and case series with meaningful outcomes. Yildiz et al. published a controlled study demonstrating significant improvements in Raynaud’s severity, digital ulcer healing and pain scores in scleroderma patients following HBOT. Other published series document improvements in modified Rodnan skin scores and hand function. We are transparent that this evidence is less extensive than for conditions like radiation injury or gas gangrene, and we discuss realistic expectations candidly at your consultation.
Many scleroderma patients with digital ulcers begin to notice improvement in ulcer appearance and pain within the first 10 to 15 sessions. The timeline for complete healing depends on ulcer size, depth, duration and the patient’s overall vascular status. Larger or longer-standing ulcers may require the full treatment course before closure is achieved. Some patients experience significant pain relief even before ulcers fully close, which meaningfully improves quality of life during treatment.
Scleroderma is not a Medicare-approved HBOT indication. However, if a scleroderma patient has a qualifying non-healing wound — such as a digital ulcer that has failed standard wound care — it may qualify for coverage under Medicare’s non-healing wound indication with appropriate documentation. Some commercial insurers may also provide coverage in this context. Our team will review your specific situation and assist with prior authorization. Self-pay pricing is available for patients without applicable coverage.
Yes. HBOT is compatible with the medications commonly used in scleroderma management, including vasodilators (nifedipine, amlodipine, sildenafil), endothelin receptor antagonists (bosentan), immunosuppressives (mycophenolate, methotrexate) and prostacyclin analogues (iloprost). We review all current medications at your initial assessment and coordinate with your rheumatologist throughout treatment.
Pulmonary involvement in scleroderma — interstitial lung disease or pulmonary arterial hypertension — requires careful evaluation before HBOT. Our medical team reviews your pulmonary function tests, echocardiogram, diffusion capacity (DLCO) and oxygen saturation to assess safety. Most patients with mild to moderate pulmonary scleroderma can safely undergo HBOT. Severe pulmonary hypertension is a relative contraindication that we assess on a case-by-case basis. Patient safety is always our first consideration.
Living with scleroderma’s effects on your skin and circulation? Ask us about HBOT
Bay Area Hyperbarics offers HBOT as an adjunctive therapy for scleroderma patients with digital ulcers, refractory Raynaud’s phenomenon and non-healing scleroderma-related wounds. Call us to schedule a consultation and discuss whether HBOT can help your specific situation.
